DOCSLIB.ORG

RELX Group Annual Reports and Financial Statements 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RELX Group Annual Reports and Financial Statements 2007 Annual Reports and Financial Statements 2007 tal Litigator ZAP Academic Press RiskView QuickLaw Matthew Bender Matthew Scirus iety Scopus Tolley’s Martindale-Hubbell Cell nes Embase To ICIS Tetrahedron Letters Engineering Village Engineering Visual Files Total Practice Advantage Practice Total Var CrossFire Beilstein CrossFire Misset Horeca alayan Law Journal Lexis.com Totaljobs.com ScienceDirect M Lawyers.com Agrarisch Dagblad Evolve Market Cast KnowHow FEM Busi Netter MIPC JurisClasseur Gray’s Anatomy Gray’s InterAction Mosby’s Nursing Consult Nursing Mosby’s File & Serve & File Chabner’s Language of Medicine of Language Chabner’s InstantID SIMA HESI m JCK Las Vegas Las JCK ELSEVIER SCIENCE & TECHNOLOGY EmpowerX Butterworths Masson PharmaPendiu lL MDConsult L Counse The The Ac REED EXHIBITIONS ELSEVIER HEALTH SCIENCES TOTAL SOLUTIONS RISK INFORMATION & ANALYTICS LEXISNEXIS INFORMATION REED ELSEVIER SOLUTIONS FOR PROFESSIONALS Information solutions for professionals Reed Elsevier is a world leading provider of professional information and online workflow solutions in the Science, Medical, Legal, Risk Information and Analytics, and Business sectors. Based in over 200 locations worldwide, we create authoritative content delivered through market leading brands, enabling our customers to find the essential data, analysis and commentary to support their decisions. ess Our content and solutions are increasingly embedded in the workflows of our customers M making them more effective and Reed Elsevier PCO ional a more valued partner. Boerderij New Scientist EDN eekblad Elsevier W MIPIM Flight Internat Estates Gazette MIPTV Interior Design Furniture Today Accurint The Lancet CounselLink MDConsult PharmaPendium Masson Butterworths EmpowerX JCK Las Vegas HESI SIMA InstantID Chabner’s Language of Medicine File & Serve Mosby’s Nursing Consult InterAction REED BUSINESS INFORMATION Gray’s Anatomy JurisClasseur Netter KnowHow Evolve Lawyers.com ScienceDirect Lexis.com CrossFire Beilstein Total Practice Advantage Engineering Village ICIS REED BUSINESS Embase Martindale-Hubbell Scopus Matthew Bender RiskView ZAP Academic Press QuickLaw Scirus Tolley’s ELSEVIER Cell Total Litigator Tetrahedron Letters Visual Files www.reedelsevier.com Variety M Our business Elsevier is a leading provider of scientific, technical and medical information > and solutions. The Science & Technology division is the world’s largest global academic journal publisher, producing over 200,000 new research articles in some 1,100 journals every year, with ScienceDirect, its flagship electronic product, Elsevier accessed by over 11 million users. The Health Sciences division publishes over 700 journals and 2,000 books and clinical reference works annually and offers an extensive portfolio of online tools in education, practitioner reference and point of care. > www.elsevier.com > For a detailed operating review turn to page 20 > For a detailed description of the business turn to page 82 LexisNexis is a leading provider of legal, tax, regulatory, risk information and > analytics, and business information solutions to professional, corporate and government customers worldwide. LexisNexis provides authoritative content through trusted market leading brands which, enabled by technology, offers LexisNexis online information solutions increasingly integrated within the customer workflow. In risk information and analytics, LexisNexis assists customers in managing risk through identity verification, employment screening and fraud prevention. > www.lexisnexis.com > For a detailed operating review turn to page 22 > For a detailed description of the business turn to page 83 Reed Business is the world’s largest business-to-business publisher and > exhibition organiser. Reed Business Information publishes over 400 trade magazines, directories and newsletters and provides over 200 online communities, job sites, lead generation, data and other online services. Reed Exhibitions Reed organises trade exhibitions and conferences internationally, with over 500 events Business in 38 countries attracting in excess of 90,000 exhibitors and more than six million visitors annually. > www.reedbusiness.com > For a detailed operating review turn to page 24 > For a detailed description of the business turn to page 84 Our strengths Our strategy We hold leadership positions in large Deliver authoritative content through global markets sustained by the leading brands increasing demand for professional Invest in new sources of content to widen information and differentiate the product offering to our customers, expanding into new We deliver authoritative content of the segments and geographic regions highest quality through market leading brands, enabling our professional Drive online solutions customers to find the essential data, Leverage our leadership brands and analysis and commentary to support authoritative proprietary content to their decisions deliver innovative, solutions-orientated products that become embedded in Our content and solutions are customers’ workflows and enable Reed increasingly embedded in our customers’ Elsevier to move up the value chain workflows making them more effective and Reed Elsevier a more valued partner Improve cost efficiency Leverage our scale, skill sets, We generate a large part of our revenues technology, resources and collective from subscriptions and other recurring experience across the business to revenue streams improve cost efficiency Our focus on operational efficiency Reshape and strengthen portfolio allows us to deliver continuous margin Allocate capital and resources, both improvement while funding investment through internal investment and in new products acquisition, to pursue opportunities that accelerate our strategic and The quality of our profits is underpinned business progress by strong cash flow generation We recruit and cultivate the best talent to serve our customers and manage our business with enterprise, professionalism and exceptional commitment Contents 02 Financial highlights 04 Chairman and Chief Executive’s report > 09 Information solutions Overview 19 Divisional summary 20 Elsevier > 22 LexisNexis 24 Reed Business Operating 26 Discontinued operations – Harcourt Education and financial 27 Chief Financial Officer’s report 27 Combined businesses review 34 Parent companies 36 Directors > 38 Corporate responsibility 42 Structure and corporate governance 51 Directors’ remuneration report Governance 76 Report of the Audit Committees 80 Description of business > 86 Resources and investment 88 Principal risks Our 90 Key performance measures business 92 Combined financial statements > 133 Summary combined financial information in euros 147 Reed Elsevier PLC annual report and financial statements Financial 167 Reed Elsevier NV annual report and financial statements 188 Additional information for US investors statements 193 Shareholder information and other 198 Principal operating locations information 8 For further information visit www.reedelsevier.com 02 Financial highlights Financial highlights Reed Elsevier combined businesses – continuing operations % change at 2007 2006 % constant For the year ended 31 December £m £m change currencies Reported figures Revenue 4,584 4,509 +2% +6% Operating profit 888 837 +6% +12% Profit before tax 812 678 +20% +26% Net borrowings 492 2,314 % change at 2007 2006 % constant For the year ended 31 December £m £m change currencies Adjusted figures Operating profit 1,137 1,081 +5% +11% Profit before tax 998 923 +8% +13% Operating cash flow 1,108 1,086 +2% +6% Operating margin 24.8% 24.0% Operating cash flow conversion 97% 100% The results of the Harcourt Education division are presented as discontinued operations and are excluded from revenue, operating profit, profit before tax, operating margin and operating cash flow. The Reed Elsevier combined financial statements are presented in pounds sterling on pages 92 to 131. The primary combined financial statements and selected notes are presented in euros on pages 133 to 146. The Reed Elsevier combined financial statements presented in euros are available on the Reed Elsevier website, www.reedelsevier.com. Parent companies – total operations % change at % constant Reed Elsevier PLC 2007 2006 change currencies Reported earnings per share 49.7p 25.6p +94% Adjusted earnings per share 35.9p 33.6p +7% +12% Dividend per share 18.1p 15.9p +14% % change at % constant Reed Elsevier NV 2007 2006 change currencies Reported earnings per share a1.10 a0.59 +86% Adjusted earnings per share a0.80 a0.76 +5% +12% Dividend per share a0.425 a0.406 +5% The Reed Elsevier combined businesses encompass the businesses of Reed Elsevier Group plc and Elsevier Reed Finance BV, together with their two parent companies, Reed Elsevier PLC and Reed Elsevier NV (the “Reed Elsevier combined businesses”). The results of Reed Elsevier PLC reflect its shareholders’ 52.9% economic interest in the Reed Elsevier combined businesses. The results of Reed Elsevier NV reflect its shareholders’ 50% economic interest in the Reed Elsevier combined businesses. The respective economic interests of the Reed Elsevier PLC and Reed Elsevier NV shareholders take account of Reed Elsevier PLC’s 5.8% interest in Reed Elsevier NV. Adjusted figures are presented as additional performance measures and are stated before amortisation of acquired intangible assets and acquisition integration costs, and, in respect of earnings, reflect a tax rate that excludes the effect of movements in deferred taxation assets and liabilities
Load more

Recommended publications
  • BOOKLIST for ADN Program Spring Quarter (January 4, 2021)
    BOOKLIST for ADN Program Spring Quarter (January 4, 2021) The following outlines the resources (textbooks, websites, media, etc.) utilized in each course. Required resources are necessary for academic success: you must obtain and study from them to succeed in a course as outlined in the course syllabus. Recommended resources provide material that will boost your academic performance in that course but are not always necessary for academic success. Faculty may or may not use recommended resources in class or during clinical. Please confer with course faculty prior to purchasing recommended resources. Use International Standard Book Numbers (ISBN) to identify the books below with any book vendor. Rented, used, and electronic formats of the resources may be available at a reduced cost to the student. A dagger (†) preceding a title indicates the resource is appropriate for renting. A keyboard symbol (⌨) preceding a title indicates the resource is available electronically/online. When renting a textbook, it may not include CDs, DVDs, or access codes for other protected electronic content, even if the book had those features when sold new. These features may be required for successful completion of the course in which the book is used. If you believe a textbook is supposed to include a disk or an unused access code, check before renting. Galen is not responsible for purchases made in error. Textbooks/resources may be used in multiple courses throughout the program. Students should verify this information via the booklist prior to purchasing/renting or returning/reselling. Galen encourages students to retain textbooks/resources as reference materials to assist throughout their nursing career.
    [Show full text]
  • EMBASE Find Quick, Relevant Answers to Your Biomedical Questions
    EMBASE Find quick, relevant answers to your biomedical questions Piotr Golkiewicz Solution Sales Manager Life Sciences Central and Eastern Europe and Russia Embase® is a registered trademark of Elsevier BV. WHAT IS EMBASE? THE WORLD’S MOST COMPREHENSIVE BIOMEDICAL RESEARCH TOOL Reliable and authoritative content to help the drug and drug-related research community advance new biomedical and pharmaceutical discoveries. Confidence Find all relevant articles that may not otherwise be found by using alternative databases Deep Biomedical Indexing All relevant, up-to-date, biomedical information from the research literature Precise Retrieval Deep and focused research using the most powerful retrieval tools 2 HOW EMBASE DELIVERS VALUE ...by including literature and Conference Scientific In Press We make sure you information resources in a proceedings Journals (unpublished) don’t miss any timely manner biomedical literature ...by reading full-text to The only close identify drugs, diseases, Deep indexing using own taxonomy alternative is adverse affects, clinical (EMTREE) reading trials, drug trade names etc. all the articles ...by enabling advanced search filters to drill down a Very powerful Good precision and comprehensive search to a recall balance relevant and manageable record Search Environment set ...by allowing users to automate Automation and searching and result management documentation E-mail Alerting API Interoperability 3 EMBASE CONTENT 4 EMBASE IS AS COMPREHENSIVE AS POSSIBLE SOURCE TEXT MINING EMBASE SCOPUS Effort / tools required / tools Effort PUBMED GOOGLE 0 % 50 % 100 % Percentage of relevant articles retrieved 5 COMPREHENSIVE CONTENT COVERAGE ON AVERAGE >5000 RECORDS ADDED EACH WORKDAY! Embase: Now covers over 8,400 journals Indexed at Embase (over 5,700 titles) Indexed by MEDLINE (e.g.
    [Show full text]
  • Orthopaedic Bioengineering Research Laboratory 2010-2011
    2010-2011 Report including the Orthopaedic Bioengineering Research Laboratory Preface It is my pleasure to present our 2010-2011 report been possible without a number of our donors from the Orthopaedic Research Center and the stepping up to provide supplemental funding. Orthopaedic Bioengineering Research Laboratory I’m particularly grateful to Mr. Jim Kennedy for at Colorado State University. Our principal focus providing supplemental operating funds and continues to be solving the significant problems in continuing the legacy of his mother, Barbara Cox equine musculoskeletal disease as can be seen in this Anthony. I’m also grateful to Abigail Kawananakoa report but we also continue to investigate questions for continued support over and above the Endowed relevant to human joint disease and techniques Chair she donated three years ago; and Herbert Allen and devices for human osteoarthritis and articular for continuing to provide considerable support for cartilage repair when the technique can also benefit investigation of cutting edge therapies. the horse. There have been a number of notable projects in this regard. The studies, led by Dr. Dave We have added an Equine Sports Medicine Frisbie at the ORC in partnership with Dr. Alan Ambulatory clinical arm to the Orthopaedic Research Grodzinsky at MIT on an NIH Program Grant in Center and also initiated two residencies in Sports cartilage repair, have been completed and results Medicine and Rehabilitation. This follows on from are still be analyzed. We have three other ongoing the accreditation of a new specialty college, the NIH grants in partnership with collaborators. One is American College of Veterinary Sports Medicine and with Dr.
    [Show full text]
  • Connections a Publication by the National Association of Realtors®
    VOLUME 17 / ISSUE 2 / SPRING 2017 COMMERCIAL CONNECTIONS A PUBLICATION BY THE NATIONAL ASSOCIATION OF REALTORS® INVESTMENT SPRINGS ETERNAL USING YOUR TIME, MONEY, & ENERGY FOR GROWTH IN THIS ISSUE: PRESIDENT’S UPDATE / Commercial Advocacy on Capitol Hill NETWORKING / Inside MIPIM 2017 ADVOCACY / Q&A With NAR’S Deputy Chief Lobbyist FEATURE / Smart Growth Grants Fund Communities PLUS / Explore New Research, IREM®’s Sustainability Certification, & more. COMMERCIAL CONNECTIONS 2017 NAR PRESIDENT Bill Brown Oakland, CA TABLE OF 2017 COMMERCIAL LIAISON Deena Zimmerman CONTENTS Chicago, IL 2017 COMMERCIAL COMMITTEE CHAIR Tray Bates, CCIM, CIPS, SIOR Corpus Christi, TX FEATURED CONTENT CHIEF EXECUTIVE OFFICER Dale A. Stinton, CAE, CMA, CPA, RCE INSIDE PERSPECTIVE: PAGE 5 SENIOR VICE PRESIDENT ONE-ON-ONE WITH NAR’S DEPUTY CHIEF LOBBYIST Spring is upon us, and the bloom of the cherry blossoms COMMERCIAL & GLOBAL SERVICES in Washington, D.C. means the arrival of my favorite Janet Branton, CAE, CIPS COMMUNITY DEVELOPMENT: PAGE 15 meeting of the year: the REALTORS® Legislative Meetings VICE PRESIDENT SMART GROWTH SPURS COMMUNITIES and Trade Expo. COMMERCIAL & GLOBAL SERVICES Jan Hope, CIPS, RCE INTERNATIONAL: PAGE 20 Members around the country have heard me say this many DIRECTOR MIPIM: STORIES OF A WORLD OF POSSIBILITIES times, but it cannot be repeated enough. 2017 is not only COMMERCIAL REAL ESTATE for the political and policy arenas, but for our own industry. Jean Maday, RCE Advocacy efforts put forth during the Legislative Meetings in ALSO IN THIS ISSUE May will ensure future success for our members. Successful DIRECTOR QUANTITATIVE & PRESIDENT’S UPDATE: PAGE 3 advocacy initiatives depend on visibility.
    [Show full text]
  • Mosby's Comprehensive Review of Radiography
    PERPUSTAKAAN PRIBADI AN-NUR YOU’VE JUST PURCHASED MORE THAN A TEXTBOOK!* Evolve Student Resources for Callaway: Mosby’s Comprehensive Review of Radiography: The Complete Study Guide and Career Planner, Seventh Edition, include the following: • Radiography Practice Exams • Flashcards • Sample Resumes and Cover Letters Activate the complete learning experience that comes with each NEW textbook purchase by registering with your scratch-off access code at http://evolve.elsevier.com/Callaway/radiography/ If you purchased a used book and the scratch-off code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above. Place Peel Off Sticker Here REGISTER TODAY! You can now purchase Elsevier products on Evolve! Go to evolve.elsevier.com/html/shop-promo.html to search and browse for products. * Evolve Student Resources are provided free with each NEW book purchase only. Mosby’s Comprehensive Review of Radiography The Complete Study Guide and Career Planner Seventh Edition This page intentionally left blank Mosby’s Comprehensive Review of Radiography The Complete Study Guide and Career Planner Seventh Edition William J. Callaway, MA, RT(R) Radiography Educator, Author, Speaker Springfield, Illinois 3251 Riverport Lane St. Louis, Missouri 63043 MOSBY’S COMPREHENSIVE REVIEW OF RADIOGRAPHY: THE COMPLETE STUDY GUIDE AND CAREER PLANNER, SEVENTH EDITION ISBN: 978-0-323-35423-3 Copyright © 2017 Elsevier Inc. All Rights Reserved. Previous editions copyrighted 2013, 2008, 2006, 2002, 2000, 1998, 1995. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher.
    [Show full text]
  • Altmetric.Com and Plumx
    This is a preprint of an article published in Scientometrics. The final authenticated version is available online at: https://doi.org/10.1007/s11192-021-03941-y A large-scale comparison of coverage and mentions captured by the two altmetric aggregators- Altmetric.com and PlumX Mousumi Karmakara, Sumit Kumar Banshalb, Vivek Kumar Singha,1 1Department of Computer Science, Banaras Hindu University, Varanasi-221005, India 2Department of Computer Science, South Asian University, New Delhi-110021, India. Abstract: The increased social media attention to scholarly articles has resulted in creation of platforms & services to track the social media transactions around them. Altmetric.com and PlumX are two such popular altmetric aggregators. Scholarly articles get mentions in different social platforms (such as Twitter, Blog, Facebook) and academic social networks (such as Mendeley, Academia and ResearchGate). The aggregators track activity and events in social media and academic social networks and provide the coverage and transaction data to researchers for various purposes. Some previous studies have compared different altmetric aggregators and found differences in the coverage and mentions captured by them. This paper attempts to revisit the question by doing a large-scale analysis of altmetric mentions captured by the two aggregators, for a set 1,785,149 publication records from Web of Science. Results obtained show that PlumX tracks more altmetric sources and captures altmetric events for a larger number of articles as compared to Altmetric.com. However, the coverage and average mentions of the two aggregators, for the same set of articles, vary across different platforms, with Altmetric.com recording higher mentions in Twitter and Blog, and PlumX recording higher mentions in Facebook and Mendeley.
    [Show full text]
  • 2017 Elsevier Foundation Annual Report
    2017 Elsevier Foundation Report Médecins Sans Frontiers doctors conduct a Phase III rotavirus vaccine trial at Epicentre’s Niger Research Center at the Maradi Hospital, which receives an annual capacity building grant of $100,000 from the Elsevier Foundation. © KRISHAN Cheyenne/MSF White City students at a recent Imperial College London workshop with the student drone society. The Elsevier Foundation supported Maker’s Challenge space will launch in September, hosting future White City students as they navigate 3D printers, tackle robotics and many other tech challenges. © Imperial College London 2017 OWSD-Elsevier Foundation woman scientist award winner Felycia Edi Soetaredjo, PhD, Lecturer at Widya Mandala Surabaya Catholic University in Surabaya, Indonesia, was recognized for her work utilizing waste and cheap materials for environmental remediation of renewable energy. © Widya Mandala Surabaya Catholic University The Elsevier Foundation 2017 Board Report 2 Contents Foreword: Youngsuk “YS” Chi, President of the Elsevier Foundation I. The Elsevier Foundation 1. Who we are 2. Our Board 3. Our Programs 4. Our Future II. Our Programs 1. Health & Innovation 2. Research in Developing Countries 3. Diversity in STM 4. Technology for Development IV. Matching Gift V. Media Outreach VI. Financial Overview VII. Appendix The Elsevier Foundation 2017 Board Report 3 The Elsevier Foundation 2017 Board Report 4 Foreword On the occasion of the September 2017 Elsevier Foundation Board Meeting It has been an incredible privilege to steer collaboration in Sustainability. The TWAS the Elsevier Foundation’s development Elsevier Foundation Program provides over the last decade. I continue to be travel grants for PhD’s and postdoc inspired by the dedication and resolve of scientists studying in sustainability fields this group as we strive to tackle important and hosts case study competitions to global challenges.
    [Show full text]
  • RELX Group Teach-In
    RELX Group Teach-In Thursday, 9th November 2017 RELX Group Teach-In Thursday, 9th November 2017 Welcome Colin Tennant Head of Investor Relations, RELX Group Opening remarks My name is Colin Tennant. I am the Head of Investor Relations at RELX Group. I have three things to do today. First is to welcome everybody. So, welcome, everybody. Second is just a little bit of housekeeping. If the fire alarm does go off during this presentation, you'll be leaving the way you came in. There will be people with fluorescent jackets to help you find the exit. Hopefully, that won't happen. And the final thing I need to do is to introduce the host for today's presentation, Chet Burchett, the Chief Executive of Reed Exhibitions, who is going to lead you through all we are going to cover for today. So, Chet over to you. Overview of Reed Exhibitions Chet Burchett Chief Executive Officer, Reed Exhibitions My Background Thank you, Colin. Good afternoon. As Colin notes, I am, indeed, Chet Burchett. I have been Chief Executive for Reed Exhibitions since 2015. I have been with the company for almost 14 years. I joined in February 2004 as President of North America. I came over from Burson-Marsteller, one of the WPP's global public relations agencies, where I had been serving as Chief Executive for their US business. Then, my role expanded for Reed to President of the Americas when I took on responsibility for our South American business which, at the time, was a small operation in Argentina and a few shows in Brazil.
    [Show full text]
  • RELX Group Annual Reports and Financial Statements 2015
    Annual Reports and Financial Statements 2015 Annual Reports and Financial Statements 2015 RELX Group is a world-leading provider of information and analytics for professional and business customers across industries. We help scientists make new discoveries, lawyers win cases, doctors save lives and insurance companies offer customers lower prices. We save taxpayers and consumers money by preventing fraud and help executives forge commercial relationships with their clients. In short, we enable our customers to make better decisions, get better results and be more productive. RELX PLC is a London listed holding company which owns 52.9 percent of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1 percent of RELX Group. Forward-looking statements The Reports and Financial Statements 2015 contain forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. These statements are subject to a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those currently being anticipated. The terms “estimate”, “project”, “plan”, “intend”, “expect”, “should be”, “will be”, “believe”, “trends” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to competitive factors in the industries in which the Group operates; demand for the Group’s products and services; exchange rate fluctuations; general economic and business conditions; legislative, fiscal, tax and regulatory developments and political risks; the availability of third-party content and data; breaches of our data security systems and interruptions in our information technology systems; changes in law and legal interpretations affecting the Group’s intellectual property rights and other risks referenced from time to time in the filings of the Group with the US Securities and Exchange Commission.
    [Show full text]
  • Beijing Hits Back After US Treasury Labels China a Currency Manipulator
    BUSINESS WITH PERSONALITY HEARTBREAK BLAST FROM THE PAST HOTEL WHEN A NEW SUPERCHARGED HOLIDAYS GO £90K CLASSIC MINI P18 WRONG P17 WEDNESDAY 7 AUGUST 2019 ISSUE 3,430 CITYAM.COM FREE CRYIN’ KING Disney investors GOVE POINTS tearful despite box office success THE FINGER CATHERINEAT NEILAN BRUSSELSthe backing of the Commons. ratification of the withdrawal agree- “We can’t have a deal that doesn’t ment, or further extension or revoca- @CatNeilan command the confidence of the gov- tion of Article 50... [I am] certainly not THE UK has accused the EU of refusing ernment, the parliament and the fatalistic about that. to budge on Brexit negotiations and in- country and that is why we have been “Our position is that the withdrawal sisted the bloc “must change its clear with the European Union that agreement, including the backstop is stance” if a no-deal exit is to be dodged. we need a new approach,” he closed, but there is always room for Ireland’s Leo Varadkar yesterday responded. talks and negotiations. We have said said he was confident a no-deal Brexit “We stand ready to engage with the we can certainly make changes to the could still be avoided, despite EU to negotiate in good faith… political declaration, and we have Prime Minister Boris Johnson We will put all our energy demonstrated before to offer clarifica- stressing the UK will leave into making sure we can tions as we did at the request of Prime the European Union “do secure that good deal. Minister May in the past.” or die”, come 31 Octo- “At the moment it’s Yesterday the pound hit its lowest ber.
    [Show full text]
  • Introduction to Ascential Our Investment Case
    INTRODUCTION TO ASCENTIAL OUR INVESTMENT CASE Clear long-term vision. Helping leading global brands connect with their customers in a data-driven world. Structural growth. Demand for information, data & analytics driven by growth of digital commerce. Market leaders. We are leaders, with a unique blend of specialisms, in the high growth areas in which we operate. Robust business model. High recurring and repeat revenue, with more than 50% revenues from digital subscription and platforms, across diverse global customer base. Attractive financial profile. Track record of high single digit revenue growth, strong margins and cash generation, supported by sound capital allocation. Introduction to Ascential 2 OUR CUSTOMER PROPOSITION Our information products and platforms support our customers to do three simple things… CREATE THE RIGHT MAXIMISE THE OPTIMISE DIGITAL PRODUCTS BRAND MARKETING COMMERCE IMPACT Know which products Know how to get Know how to execute the consumer wants maximum creativity with with excellence on the tomorrow. optimised media. winning platforms. 1. 2. 3. Introduction to Ascential 3 SEGMENTAL OVERVIEW –2019 Segment Revenue % Revenue1 Growth1 EBITDA2 Margin Business Model Advisory 10% Digital Subscriptions Product £86m 21% +8% £36m 42% & Platforms 90% Design Digital Subscriptions Advisory & Platforms 11% Marketing £136m 32% +9% £51m 37% 37% Events 52% Advisory 6% Digital Subscriptions & Sales - Platforms 94% Digital £90m 22% +21% £13m 15% Commerce Sales - Digital Subscriptions & Events Platforms 4% Non Digital £68m 16%
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]